Berlin, 26 March 2020. Eckert & Ziegler BEBIG has received CE approval for the world's first applicators manufactured by 3D printing and designed for the treatment of gynecological tumors. Made of biocompatible and sterile plastic, the attachments extend the range of applications of conventional applicators. They are now also suitable for targeted, needle-assisted brachytherapy using HDR afterloading and can significantly increase the 3-year survival rate of cancer patients.
"Thanks to the new applicator add-on kits, we can now offer patients with advanced cervical cancer an optimal therapy that can be used to treat tumors with complex volumes that are difficult to properly cover. At the same time, it facilitates our work process, as the applicator is already delivered sterile. In order to be able to treat the patient-specific findings even better, the add-on kits are available in fifteen different forms," explained Professor Dr. Jean-Michel Hannoun-Levi, Head of the Radiotherapy Department at the Centre Antoine Lacassagne in Nice.
"The CE mark is an important milestone for us, as the add-on kits are the world's first 3D printed medical product family approved for needle-assisted brachytherapy", said Dr. Harald Hasselmann, member of the Executive Board of Eckert & Ziegler AG. "The 3D printing process, which has been specially developed and validated for the manufacture of sterile medical products, opens up completely new possibilities for the further development of our product portfolio and thus for the treatment of many types of cancer".
The add-on kits fit to nearly all common HDR treatment devices and thus can be used in many clinics.
HDR (high dose rate) brachytherapy is conducted with a so-called HDR afterloader, also known as a remote afterloading system. With the help of applicators and catheters, the very small radiation source is driven from a shielded safe – located inside the afterloader – directly into or next to the tumor. A computerized treatment planning program calculates precisely how long the source has to stay and radiate at the so-called dwell positions before being driven back into the safe. HDR brachytherapy can often be performed on an out-patient basis. It is conducted in only a few treatment sessions, destroys the tumor cells and spares surrounding healthy tissue as the radiation is applied from within the tumor. This noticeably increases the patient’s quality of life.
About Eckert & Ziegler BEBIG
My partner in brachytherapy and radiation therapy
Eckert & Ziegler BEBIG is a global provider of radiotherapy products and a leader in brachytherapy in Europe. The company’s offices and subsidiaries are located throughout Europe, Asia, and the United States. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product lines. In recent years, Eckert & Ziegler BEBIG has grown through the acquisitions of US-based Mick Radio-Nuclear Instruments, Inc. and the x-ray device manufacturer WOLF-Medizintechnik GmbH (WOmed). Eckert & Ziegler BEBIG is the oldest subsidiary of the Eckert & Ziegler Group. The Eckert & Ziegler Group is one of the world's largest providers of isotope technology for medical, scientific, and industrial use. The core businesses of the Group are cancer therapy, industrial radiometry, and nuclear-medical imaging.
Eckert & Ziegler BEBIG Contact Person:
Marketing Communication Manager